Brain Cancer Market Expected to Achieve US$ 4.9 Billion by 2030 | CAGR 7.8%

  • Date: 30 Sep, 2023

The global brain cancer market is poised to grow at a CAGR of 7.8% from 2023 to 2030 and reach a valuation of US$ 4.9 billion by 2030 from US$ 2.9 billion in 2023. Brain cancer refers to the abnormal and uncontrolled growth of malignant cells in the brain. The rising prevalence of brain tumors globally coupled with advances in radiation therapy, surgical techniques, and the emergence of targeted therapies and immunotherapies are anticipated to drive market growth during the forecast period.

The brain cancer treatment landscape has progressed significantly with the development of techniques like stereotactic radiosurgery, robotic neurosurgery, and intraoperative imaging and navigation that have improved surgical outcomes. The discovery of molecular biomarkers has also enabled tailored targeted therapies for subsets of patients based on the genetic makeup of their tumors. Moreover, the potential of immunotherapy in the form of immune checkpoint inhibitors is being extensively evaluated in clinical trials, both as monotherapy and in combination with chemotherapy. If approved, these immunotherapies could provide a paradigm shift in the brain cancer treatment paradigm.

Furthermore, major players in the market are actively pursuing partnerships and collaborations to accelerate drug discovery and development for brain tumors. For instance, DNAtrix entered a collaboration agreement with Merck in 2022 to evaluate the combination of DNAtrix’s DNX-2401 oncolytic adenovirus with Merck’s KEYTRUDA (pembrolizumab) immunotherapy in patients with recurrent glioblastoma. Such strategic deals are creating a robust pipeline of combination therapies, expanding treatment options for patients.

North America is expected to dominate the brain cancer market with a share of 41.5% in 2023. The high incidence of malignant brain tumors, availability of advanced diagnostics and healthcare infrastructure, and the presence of leading biopharma companies like AbbVie, Amgen, Merck, and Pfizer in the region are driving the North America market. Europe accounts for the second largest share due to high healthcare expenditure and rising cases of brain tumors in countries like France, Germany, Italy, Spain, and the UK.

Key factors propelling the growth of the global brain cancer market:

  • Rising prevalence of primary malignant brain tumors globally
  • Improving diagnosis and screening rates for brain abnormalities
  • Advances in radiation therapy and surgical techniques for brain cancer
  • Emergence of targeted therapies and immunotherapies for malignant brain tumors
  • Growing geriatric population and associated increase in cancer incidence
  • Favorable government initiatives and funding for cancer research

Key players operating in the brain cancer market include Hoffmann-La Roche, AbbVie, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Merck & Co., Novocure, Varian Medical Systems, Accuray, and Elekta. These companies are engaged in developing novel therapies as well as medical devices including radiotherapy systems for the treatment of brain cancer. The brain cancer market is poised for robust growth in the coming years driven by the rising patient population and expected launches of breakthrough therapies that can significantly improve treatment outcomes and survival rates for patients.

Trends:

  • Adoption of minimally invasive techniques gaining traction
  • Combination therapies being evaluated to improve outcomes

Opportunity:

  • Expanding applications of big data and artificial intelligence in brain cancer management

Key Report Insights:

  • North America accounted for 41.5% market share in 2023 driven by high incidence, advanced healthcare infrastructure, and presence of leading companies.
  • Europe held the second largest share of 29.2% of the brain cancer market in 2023 owing to high healthcare spending, research funding, and increasing cases.
  • Leading companies operating in the brain cancer market include Hoffmann-La Roche, AbbVie, Merck & Co., Bristol-Myers Squibb, Novocure, Varian Medical Systems, Elekta, Accuray, Ion Beam Applications, and Brainlab.

Market Segmentation

By Treatment Type

  • Chemotherapy
  • Targeted drug therapy
  • Immunotherapy
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
  • GCC Countries
  • Israel,
  • South Africa
  • North Africa
  • Central Africa
  • Rest of the Middle East

Definition

“The brain cancer market refers to the industry and ecosystem centered around products, technologies, and services used in the diagnosis, treatment, monitoring, and management of brain tumors. It comprises medical device manufacturers, pharmaceutical companies, hospitals, specialty clinics, research organizations among others involved in R&D and delivery of medical care for brain cancer.”

Why iDataAcumen

Actionable Insights

Access to robust insights derived from our rich internal databases and external sources

Deep Industry Acumen

Our industry experts have a keen understanding of macro and micro economic trends

Research Customization

On-demand generation of research and insights tailored to your needs

Vast Industry Coverage

We provide market intelligence services across multiple healthcare domains